D-0120
Phase 2Small molecule
D-0120 is one of 52 small molecule programs targeting Hyperuricemia. It is currently in Phase 2.
2
Indications
6
Total Trials
0
Active Trials
51
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
47 competitors in Hyperuricemia
#DrugCompanyPhaseTrials
1Uloric
TakedaApproved
Medrol
PfizerApproved
Farxiga
AstraZenecaApproved
Alli
EEngelhard Arzneimittel GmbH & Co.KG
Approved
Tekturna
Tibotec Pharmaceuticals, IrelandApproved
Decadron
AAspen Global Incorporated
Approved
Zyloprim
Alnylam PharmaceuticalsPhase 2
Colcrys
Alnylam PharmaceuticalsPhase 2
Dotinurad
EisaiApproved
Febuxostat Tab
XXuhui Central Hospital, Shanghai
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
PK/PD3 trials
Gout1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for D-0120. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- IInventisBio Co., Ltd